Literature DB >> 26322145

Prognosis for Survival of Young Women with Breast Cancer by Quantitative p53 Immunohistochemistry.

David E Axelrod1, Kinsuk Shah2, Qifeng Yang3, Bruce G Haffty3.   

Abstract

p53 protein detected immunohistochemically has not been accepted as a biomarker for breast cancer patients because of disparate reports of the relationship between the amount of p53 protein detected and patient survival. The purpose of this study was to determine experimental conditions and methods of data analysis for which p53 stain intensity could be prognostic for survival of young breast cancer patients. A tissue microarray of specimens from 93 patients was stained with anti-p53 antibody, and stain intensity measured with a computer-aided image analysis system. A cut-point at one standard deviation below the mean of the distribution of p53 stain intensity separated patients into two groups with significantly different survival. These results were confirmed by Quantitative Nuclear Grade determined by DNA-specific Feulgen staining. P53 provided information beyond ER and PR status. Therefore, under the conditions reported here, p53 protein can be an effective prognostic factor for young breast cancer patients.

Entities:  

Keywords:  biomarker; breast cancer; image analysis; nuclear grade; p53; prognosis; survival; tissue microarray

Year:  2012        PMID: 26322145      PMCID: PMC4549804          DOI: 10.5539/cco.v1n1p52

Source DB:  PubMed          Journal:  Cancer Clin Oncol        ISSN: 1927-4858


  32 in total

Review 1.  p53 and human cancer: the first ten thousand mutations.

Authors:  P Hainaut; M Hollstein
Journal:  Adv Cancer Res       Date:  2000       Impact factor: 6.242

2.  p53 Alterations and protein accumulation in benign breast tissue and breast cancer risk: a cohort study.

Authors:  Thomas E Rohan; Shu-Qiu Li; Robert Hartwick; Rita A Kandel
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-07       Impact factor: 4.254

Review 3.  A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers.

Authors:  Robert L Camp; Veronique Neumeister; David L Rimm
Journal:  J Clin Oncol       Date:  2008-10-20       Impact factor: 44.544

4.  Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma.

Authors:  D Gancberg; A Di Leo; G Rouas; T Järvinen; A Verhest; J Isola; M J Piccart; D Larsimont
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

Review 5.  Dangers of using "optimal" cutpoints in the evaluation of prognostic factors.

Authors:  D G Altman; B Lausen; W Sauerbrei; M Schumacher
Journal:  J Natl Cancer Inst       Date:  1994-06-01       Impact factor: 13.506

6.  Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics.

Authors:  A Ringberg; L Anagnostaki; H Anderson; I Idvall; M Fernö
Journal:  Eur J Cancer       Date:  2001-08       Impact factor: 9.162

7.  X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.

Authors:  Robert L Camp; Marisa Dolled-Filhart; David L Rimm
Journal:  Clin Cancer Res       Date:  2004-11-01       Impact factor: 12.531

8.  Molecular markers for prognosis after isolated postmastectomy chest wall recurrence.

Authors:  Bruce G Haffty; Analene Hauser; Doo Ho Choi; Nicole Parisot; David Rimm; Bonnie King; Darryl Carter
Journal:  Cancer       Date:  2004-01-15       Impact factor: 6.860

9.  The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.

Authors:  S Sjögren; M Inganäs; T Norberg; A Lindgren; H Nordgren; L Holmberg; J Bergh
Journal:  J Natl Cancer Inst       Date:  1996-02-21       Impact factor: 13.506

10.  Heterogeneity Between Ducts of the Same Nuclear Grade Involved by Duct Carcinoma In Situ (DCIS) of the Breast.

Authors:  Naomi A Miller; Judith-Anne W Chapman; Jin Qian; William A Christens-Barry; Yuejiao Fu; Yan Yuan; H Lavina A Lickley; David E Axelrod
Journal:  Cancer Inform       Date:  2010-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.